Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 par value per share
-
Shares outstanding
-
73,819,979
-
Total 13F shares
-
6,219,491
-
Share change
-
-2,136,785
-
Total reported value
-
$1,678,348
-
Price per share
-
$0.27
-
Number of holders
-
43
-
Value change
-
-$765,348
-
Number of buys
-
11
-
Number of sells
-
25
Institutional Holders of RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) as of Q1 2025
As of 31 Mar 2025,
RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) was held by
43 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,219,491 shares.
The largest 10 holders included
ACADIAN ASSET MANAGEMENT LLC, VANGUARD GROUP INC, BlackRock, Inc., Palo Alto Investors LP, GEODE CAPITAL MANAGEMENT, LLC, TWO SIGMA ADVISERS, LP, AdvisorShares Investments LLC, DEUTSCHE BANK AG\, TWO SIGMA INVESTMENTS, LP, and PARSONS CAPITAL MANAGEMENT INC/RI.
This page lists
43
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.